Literature DB >> 1974858

Antagonism of the neurotoxicity due to a single administration of methylenedioxymethamphetamine.

C J Schmidt1, C K Black, V L Taylor.   

Abstract

The role of transmitter release in the serotonergic neurotoxicity of methylenedioxymethamphetamine (MDMA) was examined using treatments altering MDMA-induced release or its consequences. The long-term decrease in 5-HT concentrations and tryptophan hydroxylase activity produced by MDMA was antagonized by depletion of vesicular monoamines with reserpine or interruption of monoamine synthesis with the decarboxylase inhibitor, monofluoromethyl DOPA (dihydroxyphenylalanine). Similar results were achieved by selectively inhibiting dopamine synthesis with alpha-methyl-p-tyrosine or through bilateral lesions of the substantia nigra with 6-hydroxydopamine. The dopamine receptor antagonist haloperidol was also effective in this regard. Although these results strongly implicate dopamine release in the long-term neurochemical effects of MDMA, protection was also provided by selective 5-HT2 antagonists indicating that the neurotoxicity is dependent upon the release of both dopamine and 5-HT.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1974858     DOI: 10.1016/0014-2999(90)90245-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  14 in total

1.  L-tyrosine contributes to (+)-3,4-methylenedioxymethamphetamine-induced serotonin depletions.

Authors:  Joseph M Breier; Michael G Bankson; Bryan K Yamamoto
Journal:  J Neurosci       Date:  2006-01-04       Impact factor: 6.167

2.  Concurrent Inhibition of Vesicular Monoamine Transporter 2 Does Not Protect Against 3,4-Methylenedioxymethamphetamine (Ecstasy) Induced Neurotoxicity.

Authors:  Aram B Cholanians; Andy V Phan; Serrine S Lau; Terrence J Monks
Journal:  Toxicol Sci       Date:  2019-07-01       Impact factor: 4.849

3.  A study on the mechanism by which MDMA protects against dopaminergic dysfunction after minimal traumatic brain injury (mTBI) in mice.

Authors:  S Edut; V Rubovitch; M Rehavi; S Schreiber; C G Pick
Journal:  J Mol Neurosci       Date:  2014-08-16       Impact factor: 3.444

4.  Electrophysiological, biochemical and behavioral evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic function.

Authors:  M G Palfreyman; C J Schmidt; S M Sorensen; M W Dudley; J H Kehne; P Moser; M W Gittos; A A Carr
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

5.  Studies on the role of dopamine in the degeneration of 5-HT nerve endings in the brain of Dark Agouti rats following 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') administration.

Authors:  M I Colado; E O'Shea; R Granados; B Esteban; A B Martín; A R Green
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

6.  The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA ('ecstasy')-induced degeneration of 5-HT nerve endings in rat brain.

Authors:  V Sanchez; J Camarero; B Esteban; M J Peter; A R Green; M I Colado
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

7.  Vesicular monoamine transporter 2 and the acute and long-term response to 3,4-(±)-methylenedioxymethamphetamine.

Authors:  Lucina E Lizarraga; Aram B Cholanians; Andy V Phan; Joseph M Herndon; Serrine S Lau; Terrence J Monks
Journal:  Toxicol Sci       Date:  2014-11-04       Impact factor: 4.849

Review 8.  Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function.

Authors:  M Isabel Colado; Esther O'Shea; A Richard Green
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

Review 9.  The role of oxidative stress, metabolic compromise, and inflammation in neuronal injury produced by amphetamine-related drugs of abuse.

Authors:  Bryan K Yamamoto; Jamie Raudensky
Journal:  J Neuroimmune Pharmacol       Date:  2008-08-15       Impact factor: 4.147

Review 10.  Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview.

Authors:  João Paulo Capela; Helena Carmo; Fernando Remião; Maria Lourdes Bastos; Andreas Meisel; Félix Carvalho
Journal:  Mol Neurobiol       Date:  2009-04-17       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.